Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $8.48 for the day, up 2.05% from the previous closing price of $8.31. In other words, the price has increased by $2.05 from its previous closing price. On the day, 3.14 million shares were traded. NTLA stock price reached its highest trading level at $8.835 during the session, while it also had its lowest trading level at $8.34.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.77 and its Current Ratio is at 5.77. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.22.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’25 when Clark Eliana sold 679 shares for $8.99 per share. The transaction valued at 6,104 led to the insider holds 95,369 shares of the business.
BASTA JAMES sold 2,572 shares of NTLA for $23,122 on Mar 04 ’25. The EVP, General Counsel now owns 111,925 shares after completing the transaction at $8.99 per share. On Jan 29 ’25, another insider, Bhanji Muna, who serves as the Director of the company, sold 265 shares for $9.97 each. As a result, the insider received 2,642 and left with 19,468 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 877824128 and an Enterprise Value of 486511072. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.17 while its Price-to-Book (P/B) ratio in mrq is 0.99. Its current Enterprise Value per Revenue stands at 8.406 whereas that against EBITDA is -0.928.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.33, which has changed by -0.6037383 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.18, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -4.35%, while the 200-Day Moving Average is calculated to be -44.60%.
Shares Statistics:
NTLA traded an average of 3.38M shares per day over the past three months and 2818180 shares per day over the past ten days. A total of 102.03M shares are outstanding, with a floating share count of 97.42M. Insiders hold about 5.89% of the company’s shares, while institutions hold 92.60% stake in the company. Shares short for NTLA as of 1744675200 were 28509745 with a Short Ratio of 8.44, compared to 1741910400 on 26688670. Therefore, it implies a Short% of Shares Outstanding of 28509745 and a Short% of Float of 31.3.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 18.0 analysts analyze and rate the current performance of Intellia Therapeutics Inc (NTLA) in the stock market.The consensus estimate for the next quarter is $-1.16, with high estimates of $-0.85 and low estimates of $-1.39.
Analysts are recommending an EPS of between $-3.19 and $-5.71 for the fiscal current year, implying an average EPS of $-4.72. EPS for the following year is $-4.46, with 24.0 analysts recommending between $-1.1 and $-6.1.
